ApoA-I inhibitors are compounds that belong to a chemical class designed to interact with and modulate the activity of apolipoprotein A-I (apoA-I). ApoA-I is a protein that plays a crucial role in lipid metabolism and transport, particularly in the formation of high-density lipoproteins (HDL) or good cholesterol. These inhibitors are developed to target the binding sites or interactions of apoA-I with lipids and other proteins involved in lipoprotein assembly and function.
By targeting apoA-I, these inhibitors provide a means to explore the intricate processes of HDL formation and cholesterol transport within the body. ApoA-I inhibitors enable researchers to investigate how modulating apoA-I's interactions with lipids influences the assembly, stability, and functionality of HDL particles. Additionally, studying the effects of apoA-I inhibitors may offer insights into their roles in cardiovascular health, lipid disorders, and other related conditions. Overall, apoA-I inhibitors serve as valuable tools for unraveling the complex interplay of proteins and lipids in maintaining lipid homeostasis and overall metabolic balance.
더보기
제품명 | CAS # | 카탈로그 번호 | 수량 | 가격 | 引用 | RATING |
---|---|---|---|---|---|---|
Anacetrapib | 875446-37-0 | sc-364404 sc-364404A | 10 mg 50 mg | $615.00 $1785.00 | ||
ApoA-I 수치 및 관련 지질 대사를 조절하는 CETP 억제제입니다. | ||||||
Dalcetrapib | 211513-37-0 | sc-364479 sc-364479A | 10 mg 50 mg | $720.00 $1900.00 | ||
ApoA-I 수치와 지질 대사에 영향을 미치는 CETP 억제제. | ||||||
RVX 208 | 1044870-39-4 | sc-472700 | 10 mg | $340.00 | ||
BET 브로모도메인 억제를 통해 ApoA-I 전사를 증가시킵니다. |